NCT03415399 is a Phase 1 clinical trial of ET190L1 ARTEMIS™ T cells in Lymphoma, B-Cell, sponsored by Eureka Therapeutics Inc..

Who is sponsoring NCT03415399?

NCT03415399 is sponsored by Eureka Therapeutics Inc..

What drugs are being tested in NCT03415399?

Interventions in NCT03415399: ET190L1 ARTEMIS™ T cells.

What condition does NCT03415399 study?

NCT03415399 studies Lymphoma, B-Cell.

Is NCT03415399 still recruiting?

NCT03415399 is currently completed. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT03415399

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Completed Phase 1 Last updated 16 March 2021

What this trial tests

Phase 1 trial testing ET190L1 ARTEMIS™ T cells in Lymphoma, B-Cell in 4 participants. Completed in 31 December 2020.

Timeline

9 September 2017

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Eureka Therapeutics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	9 September 2017
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

ET190L1 ARTEMIS™ T cells — full drug profile →

Conditions studied

Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →

Sponsor

Eureka Therapeutics Inc. — full company profile →

Who can join

18 and older, any sex, with Lymphoma, B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to determine the safety, including potential dose limiting toxicities, of ET190L1 ARTEMIS™ T cells and the duration of in vivo survival of ET190L1 ARTEMIS™ T cells in patients with relasped/refractory B-cell lymphoma. For patients with detectable disease, the study will also measure anti-tumor responses after ET190L1 ARTEMIS™ cell infusions.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
γδ T cells in immunotherapies for B-cell malignancies.
Rimailho L, Faria C, Domagala M, Laurent C, et al · · 2023 · cited 9× · PMID 37426670 · DOI 10.3389/fimmu.2023.1200003
The capability of heterogeneous γδ T cells in cancer treatment.
Yan W, Dunmall LSC, Lemoine NR, Wang Y, et al · · 2023 · cited 7× · PMID 38077392 · DOI 10.3389/fimmu.2023.1285801

Verify or expand the search:

Other trials of ET190L1 ARTEMIS™ T cells

Trials testing the same drug.

NCT03379493 — Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma · Phase 1 · terminated

Other recruiting trials for Lymphoma, B-Cell

Currently open trials in the same condition.

NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting

Other Eureka Therapeutics Inc. trials

Trials by the same sponsor.

NCT04634357 — ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT04864054 — T-Cell Therapy (ECT204) in Adults With Advanced HCC · Phase 1, PHASE2 · recruiting
NCT04502082 — Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) · Phase 1 · terminated
NCT03998033 — Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma · Phase 1 · terminated
NCT03379493 — Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03415399 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eureka Therapeutics Inc.
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03415399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing